Head To Head Comparison Of Chads₂, Cha₂ds₂ Vasc, Cha₂ds₂ Va, Has Bled, And Helt E₂s₂ Scores In Edoxaban Tr

Head-to-head comparison of CHADS2, CHA2DS2-VASc, Table 1. Baseline demographics and clinical characteristics of patients with AFa Table 2. Pairwise comparisons of Uno’s C-statistics for predicting two-year effectiveness outcomesa,b,c CHA2DS2-VA, HAS-BLED,... More

Head-to-head comparison of CHADS2, CHA2DS2-VASc, Table 1. Baseline demographics and clinical characteristics of patients with AFa Table 2. Pairwise comparisons of Uno’s C-statistics for predicting two-year effectiveness outcomesa,b,c CHA2DS2-VA, HAS-BLED, and HELT-E2S2 scores in Global N = 26,805 Comparator CHADS2 CHA2DS2-VASc CHA2DS2-VA HELT-E2S2 edoxaban-treated atrial fibrillation patients: A 2-year Age, years, mean ± SD 73.6 ± 9.70 Reference analysis from the ETNA-AF Global Program In risk score Sex, male, n (%) Location, n Europe 15,573 (58.1) 13,164 CHADS2 NA −0.005 (−0.019, 0.009), 0.4728 0.003 (−0.005, 0.012), 0.4306 0.001 (−0.022, 0.024), 0.9346 Chun-Chieh Wang1, Ching-Ya Huang2, Matthew Clasen3, Johanna Van Zyl3, Martin Unverdorben3, on behalf of the comparison of Japan Other Asian countries (Hong Kong, South Korea, 10,342 3,299 CHA2DS2-VASc 0.005 (−0.009, 0.019), 0.4728 NA 0.008 (−0.002, 0.018), 0.0993 0.006 (−0.016, 0.028), 0.5899 Thailand, Taiwan) Global ETNA-AF investigat Less